Replies to post #424227 on Amarin Corp Plc (AMRN)

[JRoon71]

Great points, Zip.

I think these are the most critical for a buyer:

-Potential buyers are waiting to see more European approvals for the sale of Vascepa
-Buyers want to know about what European National Health Services will be willing to pay for Vascepa
-The same holds true for China

From a risk perspective, I think they need to know that the "Big 3" in Europe will approve and reimburse, and at a reasonable price. Because once those prices are locked in, that's pretty much it. Without them, Europe revenue is dead. And Italy, France, and Germany represent a huge portion of EU revenue. Those three represent nearly half of the EU population (and is about 2/3 the size of the U.S.).

Germany, UK, Italy, France, and Spain = U.S. population

[Jasbg]

zip, I hope the Denner, Holt team - makes themself visible (knocks the door) at Novo Nordisk - the European Pharma Company that is absolutely flying for the moment.

Some poster here - a few weeks back argued brilliantly 'why Amarin CDV fighting drug Vascepa / Vazkepa' - will fit perfectly into an area were NOVO right now can improve in their sortiment of successful drugs 🙂

[Johnniegalan]

zip…again, why no credible offer (credible offer would have to be taken to shareholders and disclosed) in 10 years…..Z was trying to sell, his successor was open to offer, the prior Board was motivated to sell during proxy contest (to save embarrassment of getting voted out)…not even credible low ball offer……why?

[seve333]

Yes but the problem is many of the things you say are years away. I thought Germany approval would not even come for at least another year minimum if it actually gets approved. We are looking at 2026 at the very earliest for Europe revenue to probably be any good. So a sale maybe by 2027 at the earliest which is kind of depressing given this has been nothing but dead money for years now. The buyback offers a small glimmer of hope but who knows when that will get approved.